Immunotherapy drug nivolumab tested in young brain cancer patients
NCT ID NCT04323046
First seen Jun 18, 2026 · Last updated Jun 23, 2026 · Updated 1 time
Summary
This early-phase trial is testing the immunotherapy drug nivolumab in children and young adults whose high-grade glioma has come back or is getting worse. Participants receive the drug before and after surgery to remove as much of the tumor as possible. The main goals are to check for side effects and to see if the drug changes certain genetic signals in the tumor. Only 9 people are enrolled, so this is a very small study focused on safety and biological activity, not yet on proving the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Children's Hospital of Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Children's National Hospital
Washington D.C., District of Columbia, 20310, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Children's Hospital & Health Center
Durham, North Carolina, 27705, United States
-
Hackensack Meridian Children's Health at Joseph M. Sanzari Children's Hospital
Hackensack, New Jersey, 07601, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Perth Children's' Hospital
Perth, Western Australia, 6009, Australia
-
Queensland Children's Hospital
South Brisbane, Queensland, 4101, Australia
-
Rady Children's Hospital
San Diego, California, 92123, United States
-
Riley Children's Hospital
Indianapolis, Indiana, 46202, United States
-
Royal Children's Hospital
Parkville, Victoria, 3052, Australia
-
Sydney Children's Hospital
Sydney, New South Wales, 1291, Australia
-
The Children's Hospital at Westmead
Westmead, New South Wales, 2152, Australia
-
University of Alabama at Birmingham, Children's of Alabama
Birmingham, Alabama, 35233, United States
-
University of California, San Francisco
San Francisco, California, 94115, United States
-
University of Florida
Gainesville, Florida, 32611, United States
-
University of Utah
Salt Lake City, Utah, 84113, United States
-
Washington University St. Louis
St Louis, Missouri, 63110, United States
-
Women's and Children's Hospital
North Adelaide, South Australia, 5006, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo), an immunotherapy drug
What this could lead to
If it works, this could point toward a new treatment option for young people with recurrent high-grade glioma, a type of brain cancer with few effective therapies.
What could go wrong
This is a very early, small pilot study with only 9 participants. It primarily looks at safety and biological changes, not yet at curing the disease. The drug may not work or could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.